BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that the company will be presenting its DNA vaccine technology platform and the development of universal influenza vaccine candidates at the upcoming World Vaccine Congress to be held in Washington, DC from April 19-22.
